Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
179 hedge funds and large institutions have $835M invested in Acorda Therapeutics in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 55 reducing their positions, and 19 closing their positions.
154% more call options, than puts
Call options by funds: $38.5M | Put options by funds: $15.2M
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
16% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 55
3% more funds holding
Funds holding: 174 → 179 (+5)
18% less capital invested
Capital invested by funds: $1.01B → $835M (-$180M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$16.5M |
| 2 |
BlackRock
New York
|
+$15.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.23M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$29.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7.81M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.62M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.82M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$3.43M |
ACOR Hedge Fund Activity: Q4 2018 in Review
179 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2018, worth a combined $835M — down 18% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ACOR positions and 19 closed out — a net gain of 7 holders — while 64 added to existing stakes and 55 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $16.5M. The largest seller was Scopia Capital Management, cutting an estimated $29.3M.
- 179 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2018, up from 174 in Q3 2018.
- Funds reported $835M of Acorda Therapeutics stock for Q4 2018, down 18% quarter-over-quarter.
- 26 funds opened new Acorda Therapeutics positions in Q4 2018 and 19 closed out, a net change of +7 holders.
- The largest Acorda Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $16.5M added.
- The largest Acorda Therapeutics seller in Q4 2018 was Scopia Capital Management, an estimated $29.3M sold.
Based on aggregated 13F filings for Q4 2018.